A randomized, open-label, multicenter, comparator-controlled study to examine the effects of exenatide long-acting release on glucose control (HbA1c) and safety in subjects with type 2 diabetes mellitus managed with diet modification and exercise and/or oral anti-diabetic medications

Trial Profile

A randomized, open-label, multicenter, comparator-controlled study to examine the effects of exenatide long-acting release on glucose control (HbA1c) and safety in subjects with type 2 diabetes mellitus managed with diet modification and exercise and/or oral anti-diabetic medications

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms DURATION-1
  • Sponsors AstraZeneca; Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2016 Results from extension part over 7 years presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
    • 25 Aug 2015 Protocol has been amended to change in the study design from crossover to parallel, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top